Business, energy, technology, markets and global industry news from Business News Today

ECLIPSE-1

PharmaDeviceNews ECLIPSE-1
AusperBio’s AHB-171 clinical study marks the first patient dosing of its investigational liver-targeted siRNA candidate for chronic hepatitis B, expanding the company’s pursuit of a functional HBV cure. Representative image.
Pharma & Biotech

Vir Biotechnology’s ECLIPSE-1 data arrive Sunday. Can monthly therapy challenge Hepcludex?

Vir Biotechnology will reveal ECLIPSE-1 hepatitis delta results on November 8. Examine clinical endpoints, Hepcludex competition and regulatory stakes.

Read More